Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (3369)	6/29/1999 10:06:00 AM
From: j_fir2	Respond to of 10280

SEC said to slap NYSE Report said to fault Big Board for lax oversight in illegal trading case June 29, 1999: 8:11 a.m. ET fn.com NEW YORK (CNNfn) - The New York Stock Exchange reportedly faces a critical report by U.S. regulators that the exchange didn't properly handle a case of illegal trading on its floor. The U.S. Securities and Exchange Commission will reach a settlement with the Big Board soon as part of an "administrative proceeding," the Wall Street Journal reported Tuesday. The SEC will find the exchange, which is self-regulating, didn't properly administer securities law and the agency will call for better surveillance and systems at the NYSE, the Journal said. The exchange, which reportedly won't face a censure or fines, isn't expected to admit or deny the findings. The probe results from charges brought in early 1998 against eight independent floor brokers, the non-Big Board brokerage Oxford Corp. and two of its principals. They all pled guilty to charges that related to false order-writing at the exchange. Spokesmen for the SEC and the Big Board could not be reached for comment early Tuesday

To: Don Miller who wrote (3369)	6/29/1999 12:37:00 PM
From: M. Ramle	Read Replies (3) \| Respond to of 10280

Don: If my notes are correct, I believe that SEPR is currently giving an Analyst Luncheon presentation in NY City today. Do you know anything about it ??? Mazen

To: Don Miller who wrote (3369)	6/29/1999 1:29:00 PM
From: Don Miller	Read Replies (1) \| Respond to of 10280

YC,MDs Xopenex experience,& JNJ considered buyout upon profit- messages 1100 & 1102-: bbeckord (56/M/boulder,colorado) 06/29/1999 11:52 am EDT I adminstered Xopenex to a patient in my emergency room last night who indicated he was allergic to albuterol in the past. He was a 76 y/o male with severe COPD with difficulty breathing. The patient had developed tingling in his mouth, irritation in his eyes, tachycardia, and a dramatic reduction in his PEFR to the point of needing intubation. His symptoms disappeared when albuterol was withdrawn and atrovent adminstered. I had him on a monitor, so I decided to give him an SVN of Xopenex. With one adminstration of Xopenex, his PEFR went from 180 to 300, he had no tingling in his mouth, his heart rate did not increase, and he showed no signs of tremor. This drug certainly does work, and if we only need to adminster it every 8 hours, it will be a big success. At the annual meeting, Barberich indicated J&J had looked at buying the company, but elected to pass until Sepracor is profitable. They want any purchase to be accretive to earnings. J&J indicated they would look at them at a later date. Also, he said they would like to split the stock if it goes above $100.00. They want to put the stock in the hands of more individual investors and be less susceptible to the vagaries of institutions. They are going to do more road shows this year to help diversify their investors. __________________________________________________________________ Buyout bbeckord (56/M/boulder,colorado) 06/29/1999 01:05 pm EDT It came from the horses mouth in conversations immediately after the formal part of the annual meeting.